Market cap
Current P/E
Forward P/E

About

Deutsche Biotech Innovativ AG operates as a biotechnology company in Germany. The company develops Adrecizumab, an antibody-based therapy that has completed the Phase I/II clinical trial for the treatment of septic shock. It also focuses on the development of various drugs for the treatment of solid tumor, organ failure, rosacea, neurodermatitis, pharyngitis, and Alzheimer's diseases.

Similar securities

Based on sector and market capitalization

Report issue